natgillin/translations-raw huggingface dataset:
In patients with chronic renal failure, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommended in section 4.2. In clinical studies, an increased risk of death, serious cardiovascular or cerebrovascular events including stroke, and vascular access thrombosis was observed when ESAs were administered to target a haemoglobin of greater than 12 g/dl (7.5 mmol/l).
Kod bolesnika s kroničnim zatajenjem bubrega, koncentracija održavanja hemoglobina ne smije prijeći gornju granicu preporučene ciljne koncentracije hemoglobina u dijelu 4.2. U kliničkim studijama povećani rizik od smrti, ozbiljnih kardiovaskularnih ili cerebrovaskularnih događaja uključujući moždani udar i vaskularnu trombozu na mjestu primjene su primijećeni kada su LSE primjenjivani radi postizanja ciljne koncentracije hemoglobina više od 12 g/dl (7,5 mmol/l).
In patients with chronic renal failure, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommended in section 4.2. In clinical trials, an increased risk of death and serious cardiovascular events or cerebrovascular events including stroke was observed when erythropoiesis stimulating agents (ESAs) were administered to target a haemoglobin of greater than 12 g/dl (7.5 mmol/l).
U bolesnika s kroničnim zatajenjem bubrega koncentracija hemoglobina tijekom održavanja ne smije premašiti gornju granicu ciljne koncentracije hemoglobina preporučene u dijelu 4.2. U kliničkim ispitivanjima primijećen je povećan rizik od smrti i ozbiljnih kardiovaskularnih događaja ili cerebrovaskularnih događaja uključujući moždani udar, kada su primjenjivani lijekovi za stimulaciju eritropoeze, radi postizanja ciljnog hemoglobina višeg od 12 g/dl (7,5 mmol/l).
In patients with chronic renal failure, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommended in section 4.2. In clinical trials, an increased risk of death, serious cardiovascular events or cerebrovascular events including stroke were observed when ESAs were administered to target a haemoglobin of greater than 12 g/dl (7.5 mmol/l).
Kod bolesnika s kroničnim zatajenjem bubrega, održavana koncentracija hemoglobina ne bi trebala prijeći gornju granicu ciljne koncentracije hemoglobina preporučene u odjeljku 4.2. U kliničkim ispitivanjima primijećen je povećan rizik od smrti, ozbiljnih kardiovaskularnih ili cerebrovaskularnih događaja uključujući inzult, ako su ESA lijekovi primijenjeni za postizanje ciljnog hemoglobina većeg od 12 g/dl (7,5 mmol/l).
In patients with chronic renal failure, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommended in section 4.2. In clinical trials, an increased risk of death, serious cardiovascular events or cerebrovascular events including stroke were observed when ESAs were administered to target a haemoglobin of greater than 12 g/dl (7.5 mmol/l).
Kod bolesnika s kroničnim zatajenjem bubrega, održavana koncentracija hemoglobina ne bi trebala prijeći gornju granicu ciljne koncentracije hemoglobina preporučene u odjeljku 4.2. U kliničkim ispitivanjima primijećen je povećan rizik od smrti, teških kardiovaskularnih ili cerebrovaskularnih događaja uključujući inzult, ako su ESA lijekovi primijenjeni za postizanje ciljnog hemoglobina većeg od 12 g/dl (7,5 mmol/l).
In patients with chronic renal failure, the maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommended in section 4.2. In clinical trials, an increased risk of death and serious cardiovascular events was observed when epoetins were administered to target a haemoglobin level in excess of 12 g/dl (7.45 mmol/l).
U bolesnika s kroničnim zatajenjem bubrega, održavana vrijednost koncentracije hemoglobina ne smije prijeći gornju granicu ciljne koncentracije hemoglobina preporučene u dijelu 4.2 U kliničkim ispitivanjima povećani rizik od smrti i ozbiljnih kardiovaskularnih događaja zabilježen je tijekom primjene epoetina za postizanje razina hemoglobina viših od 12 g/dl (7,45 mmol/l).
In patients with chronic renal impairment whose creatinine clearance is < 30 ml/min and who are not receiving regularly scheduled haemodialysis, the recommended dose is reduced to either 1000 mg administered as a single infusion or 750 mg followed one week later by 375 mg (see section 5.2).
U bolesnika s kroničnim oštećenjem bubrega čiji je klirens kreatinina < 30 ml/min i koji se redovito ne podvrgavaju hemodijalizi, preporučena doza se smanjuje na 1000 mg dalbavancina u obliku jednokratne infuzije ili 750 mg nakon koje tjedan dana kasnije slijedi doza od 375 mg (vidjeti dio 5.2).
In patients with cirrhosis and in liver transplant recipients, treatment cessation is not recommended. (see section 5.1).
U bolesnika s cirozom jetre i bolesnika s transplantiranom jetrom, ne preporučuje se prestanak liječenja (vidjeti dio 5.1).
In patients with class II disease, Tracleer caused the resistance of the blood vessels to decrease by 23% compared with placebo after six months of treatment, but the distance the patients could walk over six minutes was similar in the two groups.
U bolesnika sa stupnjem II bolesti, Tracleer je uzrokovao smanjivanje otpornosti krvnih žila za 23% u usporedbi s placebom nakon šest mjeseci liječenja, no udaljenost koju je bolesnik mogao prijeći u razdoblju od šest minuta bila je slična u obje grupe.
In patients with CLL, tumour lysis syndrome (TLS) may occur with use of ofatumumab.
Uz primjenu ofatumumaba u bolesnika s KLL-om može doći do sindroma lize tumora (TLS; eng. tumour lysis syndrome).
In patients with CML in other phases (accelerated, myeloid blast and lymphoid blast) and in ALL, between a quarter and a third of the patients showed a complete response.
U bolesnika sa KML-om u drugim fazama (ubrzana, mijeloično blastična i limfoidno blastična) te u ALL, potpuni odgovor pokazala je četvrtina i trećina bolesnika.
In patients with combined severe congenital protein C deficiency and with APC resistance, there are limited clinical data to support the safety and efficacy of CEPROTIN.
Kod pacijenata s kombiniranim teškim prirođenim nedostatkom proteina C i APC rezistencijom postoje ograničeni klinički podaci koji podupiru sigurnost i djelotvornost lijeka CEPROTIN.
In patients with compensated liver disease, these increases in serum ALT are generally not accompanied by an increase in serum bilirubin concentrations or hepatic decompensation.
U pacijenata s kompenziranom bolešću jetre ovi porasti razine serumskog ALT-a obično nisu popraćeni porastom serumske koncentracije bilirubina ili dekompenzacijom jetre.
In patients with congenital QT syndromes (see section 4.4)
U bolesnika s kongenitalnim QT sindromima (vidjeti dio 4.4).
In patients with Crohn's disease mean steady-state serum trough concentrations were 13.0 mcg/ml (SD ± 9.08) and 34.8 mcg/ml (SD ± 22.55), respectively.
U bolesnika s Crohnovom bolešću, srednja vrijednost najniže ravnotežne serumske koncentracije bila je 13,0 µg/ml (SD ± 9,08) odnosno 34,8 µg/ml (SD ± 22,55).
In patients with Crohn’s disease a reduction of the number of cells expressing inflammatory markers in the colon including a significant reduction of expression of TNFα was seen.
U bolesnika s Crohnovom bolešću primijećeno je smanjenje broja stanica u debelom crijevu koje eksprimiraju markere upale, uključujući i značajno sniženje ekspresije TNFα.
In patients with Crohn’s disease, a reduction of the number of cells expressing inflammatory markers in the colon including a significant reduction of expression of TNFα was seen.
U bolesnika s Crohnovom bolešću primijećeno je smanjenje broja stanica u debelom crijevu koje eksprimiraju markere upale, uključujući i značajno sniženje ekspresije TNFα.
In patients with Crohn’s disease, anti-adalimumab antibodies were identified in 7/269 subjects (2.6%) and in 19/487 subjects (3.9%) with ulcerative colitis.
U bolesnika s Crohnovom bolešću protutijela na adalimumab nađena su u 7/269 (2,6%) ispitanika i u 19/487 (3,9%) ispitanika s ulceroznim kolitisom.
In patients with Crohn’s disease, following an intravenous dose of ~6 mg/kg, starting at week 8, subcutaneous maintenance dosing of 90 mg ustekinumab was administered every 8 or 12 weeks.
U bolesnika s Crohnovom bolesti, nakon intravenske doze od ~6 mg/kg, koja je započeta u 8. tjednu, supkutana doza održavanja od 90 mg ustekinumaba bila je primijenjena svakih 8 ili 12 tjedana.
In patients with Crohn’s disease, following the recommended intravenous induction dose, median peak serum ustekinumab concentration, observed 1 hour after the infusion, was 126.1 μg/mL.
U bolesnika s Crohnovom bolesti, nakon preporučene intravenske uvodne doze, medijan vršne koncentracije ustekinumaba u serumu, uočen 1 sat nakon infuzije, bio je 126,1 μg/ml.
In patients with Crohn’s disease, treatment with ustekinumab resulted in a decrease in inflammatory markers including C-Reactive Protein (CRP) and fecal calprotectin during the induction phase, which were then maintained throughout the maintenance phase.
U bolesnika s Crohnovom bolesti, liječenje ustekinumabom rezultiralo je smanjenjem upalnih markera uključujući C-Reaktivni Protein (CRP) i fekalnog kalprotektina tijekom faze uvođenja, što se zatim održalo tijekom faze održavanja.
In patients with Crohn’s disease, variability in ustekinumab CL was affected by body weight, serum albumin level, CRP, TNF antagonist failure status, sex, race (Asian versus non-Asian), and antibody to ustekinumab status while body weight was the main covariate affecting the volume of distribution.
U bolesnika s Crohnovom bolesti, na varijabilnost klirensa ustekinumaba utjecala je tjelesna težina, razina albumina u serumu, CRP, status neuspjeha TNF antagonista, spol, rasa (azijati nasparam ne- azijati), i status protutijela na ustekinumab dok je tjelesna težina bila glavna kovarijanta koja je imala ujtecaj na volumen distribucije.
In patients with CRVO, a blockage occurs in the main blood vessel that transports blood away from the retina.
U bolesnika s CRVO dolazi do začepljenja glavne krvne žile koja odvodi krv iz mrežnice.
In patients with decompensated liver disease or cirrhosis and in liver transplant recipients, treatment cessation is not recommended (see section 5.1).
U bolesnika s dekompenziranom bolešću jetre, cirozom jetre i bolesnika s transplantiranom jetrom, ne preporučuje se prestanak liječenja (vidjeti dio 5.1).
In patients with decompensated liver disease, lamivudine should always be used in combination with a second agent, without cross-resistance to lamivudine, to reduce the risk of resistance and to achieve rapid viral suppression.
Kod bolesnika s dekompenziranom bolešću jetre lamivudin se uvijek treba upotrijebiti u kombinaciji s drugim lijekom bez križne rezistencije na lamivudin kako bi se izbjegao rizik rezistencije na lamivudin i kako bi se postigla brza supresija virusa.
In patients with delayed graft function, sirolimus may delay recovery of renal function.
U bolesnika s odgođenom funkcijom presatka sirolimus može odgoditi oporavak bubrežne funkcije.
In patients with delayed graft function, sirolimus may delay recovery of renal function.
U bolesnika s odgođenom funkcijom presatka, sirolimus može odgoditi oporavak funkcije bubrega.
In patients with delayed renal graft function post-transplant, mean MPA AUC (0-12°h) was comparable to that seen in post-transplant patients without delayed graft function.
Kod bolesnika kod kojih nakon presađivanja dolazi do odgođene funkcije presađenog bubrega srednji AUC (0–12 h) MPA mogao se usporediti s AUC-om MPA bolesnika kod kojih nakon presađivanja nije došlo do odgođene funkcije presađenog bubrega.
In patients with delayed renal graft function post-transplant, mean MPA AUC (0–12 h) was comparable to that seen in post-transplant patients without delayed graft function.
Kod bolesnika kod kojih nakon presađivanja dolazi do odgođene funkcije presađenog bubrega srednji AUC (0–12 h) MPA mogao se usporediti s AUC-om MPA bolesnika kod kojih nakon presađivanja nije došlo do odgođene funkcije presađenog bubrega.
In patients with delayed renal graft function post-transplant, mean MPA AUC (0–12 h) was comparable to that seen in post-transplant patients without delayed graft function.
Kod bolesnika kod kojih nakon presađivanja dolazi do odgođene funkcije presađenog bubrega srednji AUC (0–12 sati) MPA mogao se usporediti s AUC-om MPA bolesnika kod kojih nakon presađivanja nije došlo do odgođene funkcije presađenog bubrega.
In patients with delayed renal graft function post-transplant, mean MPA AUC (0–12h) was comparable to that seen in post-transplant patients without delayed graft function.
Kod bolesnika kod kojih nakon presađivanja dolazi do odgođene funkcije presađenog bubrega srednja vrijednost AUC (0–12 h) MPA mogla se usporediti s AUC-om MPA bolesnika kod kojih nakon presađivanja nije došlo do odgođene funkcije presađenog bubrega.
In patients with delayed renal graft function post-transplant, mean MPA AUC (0–12h) was comparable to that seen in post-transplant patients without delayed graft function.
Kod bolesnika kod kojih nakon presađivanja dolazi do odgođene funkcije presađenog bubrega srednja vrijednost AUC (0–12 sati) MPA mogla se usporediti s AUC-om MPA bolesnika kod kojih nakon presađivanja nije došlo do odgođene funkcije presađenog bubrega.
In patients with diabetes mellitus requiring drug therapy, the dose of insulin and/or oral hypoglycemic medicinal product may require adjustment when somatropin therapy is initiated (see section 4.4).
Kod bolesnika s dijabetesom melitusom kojima su potrebni lijekovi, doza inzulina i/ili peroralnih hipoglikemika možda će se trebati prilagoditi početkom liječenja somatropinom (vidjeti dio 4.4).
In patients with diabetic macular oedema, the average number of letters they could read in an eye test before treatment was about 59 to 60; in patients given Eylea monthly this improved by around 12 letters, and in those given Eylea every other month by around 11 letters.
Kod bolesnika s dijabetičkim makularnim edemom, prosječni broj slova koja su mogli pročitati pri testu vida prije liječenja kretao se između 59 i 60; kod bolesnika liječenih mjesečno lijekom Eylea stanje se poboljšalo za 12 slova, a u bolesnika liječenih lijekom Eylea svaki drugi mjesec za oko 11 slova.
In patients with diffuse interstitial pulmonary fibrosis, the percent of dose recovered in expired air averaged 100% and the terminal half-life was similar to that measured in healthy volunteers.
Kod pacijenata s difuznom intersticijskom plućnom fibrozom, postotak doze koja se izlučila u izdahnutom zraku bio je u prosjeku 100%, a krajnji poluvijek sličan onome izmjerenom kod zdravih dobrovoljaca.
In patients with dry eye disease, a condition that may be considered to have an inflammatory immunological mechanism, following ocular administration, ciclosporin is passively absorbed into T- lymphocyte infiltrates in the cornea and conjunctiva and inactivates calcineurin phosphatase.
U bolesnika sa sindromom suhog oka, stanjem za koje se smatra da nastaje imunološkim upalnim mehanizmom, ciklosporin se, nakon primjene u oko, pasivno apsorbira u T-limfocitne infiltrate u rožnici i konjunktivi i inaktivira kalcineurin fosfatazu.
In patients with EBC an increase in the incidence of symptomatic and asymptomatic cardiac events was observed when Herceptin (intravenous formulation) was administered after anthracycline- containing chemotherapy compared to administration with a non-anthracycline regimen of docetaxel and carboplatin and was more marked when Herceptin (intravenous formulation) was administered concurrently with taxanes than when administered sequentially to taxanes.
U bolesnika s ranim rakom dojke zabilježeno je povećanje incidencije simptomatskih i asimptomatskih srčanih događaja pri primjeni lijeka Herceptin (intravenska formulacija) nakon kemoterapije antraciklinima, u odnosu na njegovu primjenu nakon neantraciklinskog protokola s docetakselom i karboplatinom, a taj je porast incidencije bio izraženiji kada se Herceptin (intravenska formulacija) primjenjivao istodobno s taksanima nego kada se primjenjivao nakon terapije taksanima.
In patients with EBC eligible for neoadjuvant-adjuvant treatment, Herceptin should be used concurrently with anthracyclines only in chemotherapy-naive patients and only with low-dose anthracycline regimens i.e. maximum cumulative doses of doxorubicin 180 mg/m2 or epirubicin 360 mg/m2.
U bolesnika s ranim rakom dojke koji zadovoljavaju uvjete za neoadjuvantno-adjuvantno liječenje Herceptin se smije davati istodobno s antraciklinima isključivo u bolesnika koji prije nisu primali kemoterapiju i samo uz protokole s niskim dozama antraciklina tj. onih s najvećom kumulativnom dozom doksorubicina od 180 mg/m2 ili epirubicina od 360 mg/m2.
In patients with either HBeAg positive or HBeAg negative CHB, the development of YMDD (tyrosine-methionine-aspartate-aspartate) mutant HBV may result in a diminished therapeutic response to lamivudine, indicated by a rise in HBV DNA and ALT from previous on-treatment levels.
U HBeAg pozitivnih ili HBeAg negativnih bolesnika s kroničnim hepatitisom B, razvoj mutiranog virusa tipa YMDD (tirozin-metionin-aspartat-aspartat) može dovesti do smanjenog terapijskog odgovora na lamivudin, koji se očituje porastom HBV DNK i ALT u odnosu na prijašnje razine tijekom liječenja.
In patients with end-stage renal disease (ESRD) (CrCl < 10 ml/min) requiring haemodialysis, between dialysis tenofovir concentrations substantially increased over 48 hours achieving a mean Cmax of 1,032 ng/ml and a mean AUC0-48h of 42,857 ng·h/ml.
U pacijenata s bolešću bubrega u završnoj fazi (CrCl < 10 ml/min) kojima je potrebna hemodijaliza koncentracije tenofovira između dijaliza znatno su se povećale tijekom 48 sati i dosegle srednju vrijednost Cmax od 1032 ng/ml i srednju vrijednost AUC0-48h od 42.857 ng·h/ml.
In patients with end-stage renal disease (ESRD) requiring haemodialysis, between dialysis drug exposures substantially increased over 72 hours to 53 µg•h/mL (19%) of emtricitabine, and over 48 hours to 42,857 ng•h/mL (29%) of tenofovir.
U pacijenata u terminalnom stadiju bolesti bubrega kojima je bila potrebna hemodijaliza izloženost lijekovima između dijaliza znatno je porasla i to na 53 µg•h/ml (19%) za emtricitabin tijekom 72 sata i na 42 857 ng•h/ml (29%) za tenofovir tijekom 48 sati.
In patients with ESRD on haemodialysis, approximately 30% of the emtricitabine dose was recovered in dialysate over a 3 hour dialysis period which had been started within 1.5 hours of emtricitabine dosing (blood flow rate of 400 ml/min and dialysate flow rate of approximately 600 ml/min).
U pacijenata na hemodijalizi, s bubrežnom bolešću u završnoj fazi (ESRD), u dijalizatu je izolirano približno 30% doze emtricitabina tijekom trosatne dijalize započete u roku od 90 minuta od doziranja emtricitabinom (brzina protoka krvi od 400 ml/min i brzina protoka dijalizata od približno 600 ml/min).
In patients with ESRD, sofosbuvir AUC0-inf was 28% higher when sofosbuvir was dosed 1 hour before haemodialysis compared with 60% higher when dosed 1 hour after haemodialysis, respectively.
U bolesnika sa završnim stadijem bolesti bubrega, AUC0-inf sofosbuvira bila je 28 % viša kad se doza sofosbuvira dala 1 sat prije hemodijalize u usporedbi sa 60 % višim vrijednostima kad se doza sofosbuvira dala 1 sat nakon hemodijalize.
In patients with extensive drug resistance, where SIRTURO is considered necessary beyond 24 weeks to obtain a curative treatment, a longer duration of therapy may be considered only on a case by case basis and under close safety surveillance (see sections 4.4 and 4.8).
U bolesnika s ekstenzivnom rezistencijom na lijek, kada se smatra da je SIRTURO potrebno uzimati duže od 24 tjedna da bi se postigao kurativni učinak liječenja, duže trajanje liječenja može se uzeti u obzir samo od slučaja do slučaja te uz brižan nadzor sigurnosti (vidjeti dijelove 4.4 i 4.8).
In patients with factor VII deficiency, where the recommended dose is 15 – 30 µg/kg rFVIIa, one episode of overdose has been associated with a thrombotic event (occipital stroke) in an elderly (> 80 year) male patient treated with 10 – 20 times the recommended dose.
U bolesnika s nedostatkom faktora VII, gdje je preporučena doza rFVIIa 15 - 30 µg/kg, jedan slučaj predoziranja bio je povezan s trombozom (okcipitalni moždani udar) u starijeg (> 80 godina) muškog bolesnika liječenog 10 - 20 puta većom dozom od preporučene.
In patients with flushing, the majority had flushing events that were mild or moderate in severity.
U većine takvih bolesnika, pojave crvenila uz osjećaj vrućine su bile blage ili umjerene.
In patients with gout since low doses of ASA increase urate concentrations.
U bolesnika s gihtom jer manje doze ASK povećavaju koncentracije urata.
In patients with granulomatosis with polyangiitis (Wegener’s) or microscopic polyangiitis, methylprednisolone given intravenously for 1 to 3 days at a dose of 1000 mg per day is recommended prior to the first infusion of MabThera (the last dose of methylprednisolone may be given on the same day as the first infusion of MabThera).
U bolesnika s granulomatozom s poliangitisom (Wegenerova granulomatoza) ili mikroskopskim poliangitisom se prije prve infuzije lijeka MabThera preporučuje intravenska primjena metilprednizolona u dozi od 1000 mg na dan tijekom 1 do 3 dana (posljednja doza metilprednizolona može se dati istoga dana kao i prva infuzija lijeka MabThera).
In patients with granulomatosis with polyangiitis or microscopic polyangiitis, the number of peripheral blood B cells decreased to <10 cells/μL after two weekly infusions of rituximab 375 mg/m2, and remained at that level in most patients up to the 6 month timepoint.
U bolesnika s granulomatozom s poliangitisom i mikroskopskim poliangitisom broj perifernih B stanica smanjio se na < 10 stanica/µl nakon dvije tjedne infuzije rituksimaba u dozi od 375 mg/m2 i održao na toj razini u većine bolesnika do trenutka mjere ishoda nakon 6 mjeseci.
In patients with haemophilia A (inborn factor VIII deficiency), factor VIII is missing or not working properly.
Faktor VIII ne postoji ili ne djeluje pravilno kod bolesnika s hemofilijom A (urođeni nedostatak faktora VIII).
In patients with haemophilia type A and B, there have been reports of increased bleeding while taking protease inhibitors.
Kod bolesnika s hemofilijom tipa A i B bilo je prijava o pojačanim krvarenju tijekom uzimanja inhibitora proteaze.
In patients with haemophilia type A and B, there have been reports of increased bleeding while taking this treatment or another protease inhibitor.
Tijekom liječenja ovim lijekom ili nekim drugim inhibitorom proteaze u bolesnika s hemofilijom tipa A i B prijavljeno je pojačano krvarenje.
In patients with haemophilia type A and B, there have been reports of increased bleeding while taking this treatment or another protease inhibitor.
U bolesnika s hemofilijom tipa A i B bilo je prijava pojačanog krvarenja za vrijeme uzimanja ovog lijeka ili drugih inhibitora proteaza.
In patients with haemophilia types A and B, there have been reports of increased bleeding while taking this treatment or another protease inhibitor.
U bolesnika s hemofilijom tipa A i B bilo je prijava pojačanog krvarenja za vrijeme uzimanja ovog lijeka ili drugih inhibitora proteaza.
In patients with HBeAg negative CHB (pre-core mutant) without cirrhosis, treatment should be administered at least until HBs seroconversion or there is evidence of loss of efficacy.
U HBeAg negativnih bolesnika s kroničnim hepatitisom B ("divlji tip" virusa), a bez ciroze, liječenje treba provoditi najmanje do serokonverzije HBs ili do dokazanog gubitka djelotvornosti.
In patients with HBeAg negative CHB (pre-core mutant) without cirrhosis, treatment should be administered at least until HBs seroconversion or there is evidence of loss of efficacy. .
U HBeAg negativnih bolesnika s kroničnim hepatitisom B ("divlji tip" virusa), a bez ciroze, liječenje treba provoditi najmanje do serokonverzije HBs ili dokaza o gubitku djelotvornosti.